Metagenomi, an Emeryville, Calif.-based gene editing company, extended and closed its Series A financing, bringing the round to a total of $75m.
The round was led by RA Capital Management, which joined the Series A investor syndicate, including co-lead investors Leaps by Bayer and Humboldt Fund, as well as Sozo Ventures, Agent Capital, InCube Ventures and HOF Capital, following the first close of the Series A financing, which was announced in November 2020. Andrew Levin, MD, Ph.D., Managing Director at RA Capital, will join Metagenomi’s board of directors.
The company intends to use the funds for expansion of its team and development of its therapeutic pipeline.
Led by Brian C. Thomas, Ph.D., Co-Founder and CEO, Metagenomi accelerates innovation in cell and gene therapy with a wave of proprietary CRISPR-based systems to accurately edit DNA where current technologies cannot. The company’s metagenomics-powered discovery platform and analytical expertise reveal novel cellular machinery sourced from otherwise unknown organisms and adapt and forge these naturally evolved systems into therapeutic tools that can be leveraged by partners and accelerate their own pipeline of potentially curative medicines.